Related Experiment Videos
New transcutaneous jaundice device with two optical paths
Saneyuki Yasuda1, Susumu Itoh, Kenichi Isobe
1Department of Pediatrics, Kagawa Medical University, Kagawa, Japan.
Journal of Perinatal Medicine
|March 29, 2003
Summary
The new JM-103 device accurately measures transcutaneous bilirubin (TcB) in infants, showing higher precision than the older JM-102 model when compared to total serum bilirubin (TSB) levels.
Area of Science:
- Neonatal Medicine
- Medical Devices
- Bilirubin Metabolism
Background:
- Jaundice is common in newborns, necessitating accurate bilirubin level monitoring.
- Transcutaneous bilirubinometry offers a non-invasive alternative to traditional blood tests.
- Existing devices have varying degrees of accuracy and precision.
Purpose of the Study:
- To evaluate the accuracy and precision of a new transcutaneous bilirubinometer, the JM-103, with two optical paths.
- To compare the JM-103's performance against an older device (JM-102) and total serum bilirubin (TSB) levels.
Main Methods:
- 77 Japanese infants (24 preterm, 53 term) were enrolled across three hospitals.
- Transcutaneous bilirubin (TcB) was measured using JM-103 and JM-102 devices on the forehead.
- TcB measurements were taken within 30 minutes of blood sampling for TSB determination.
Main Results:
- The JM-103 demonstrated higher correlation coefficients (r = 0.94) with TSB compared to the JM-102 across all infant groups.
- Error distribution analysis showed smaller deviations for JM-103 (0.30 +/- 1.55) versus JM-102 (0.00 +/- 2.21) when compared to TSB.
- Regression analysis indicated similar performance of JM-103 in both term and preterm infants.
Conclusions:
- The JM-103 device provides accurate and precise transcutaneous bilirubin measurements in neonates.
- The JM-103 offers improved performance over the JM-102, making it a reliable tool for non-invasive jaundice assessment.
- This new device can aid in clinical decision-making for managing hyperbilirubinemia in newborns.